- A government agency says that several promising osteoarthritis treatments are in development.
- The new therapies aim to help joints heal rather than simply treating symptoms.
- Treatment methods include bone and cartilage regeneration and living knee implants, signaling a breakthrough for those who live with osteoarthritis.
- More research on the new therapies is still needed to verify safety and effectiveness in humans.
Osteoarthritis most often affects older adults and leads to varying degrees of pain and disability. As the most common form of arthritis, it is also notoriously difficult to treat.
Unlike existing treatments for osteoarthritis, which are primarily aimed at relieving pain or replacing already damaged joints with artificial ones, the research program seeks to enable joints to heal themselves by regenerating bone and cartilage.
This breakthrough could transform the lives of millions who live with osteoarthritis by restoring natural joint function and eliminating the need for joint replacement surgeries.
Human trials are expected to begin within the next year, marking a potential turning point in osteoarthritis care.
Osteoarthritis occurs when joint tissue is damaged due to aging, obesity, injury, or overuse. It can also be associated with congenital defects or a family history of the disease.
The NITRO program focuses on helping joints heal themselves through three key approaches: regenerating bone, regenerating cartilage, and developing living knee implants made from human tissue.
Duke University has developed two injectable, time-released combination drug formulations that stimulate bone and cartilage regrowth in OA-damaged joints.
These injectable therapies can be used alone or together and are designed for infrequent administration — only once per year — to relieve pain and restore joint function.
The researchers created an intravenous time-release formulation to promote cartilage repair across multiple joints, reducing the need for multiple injections.
The University of Colorado Boulder has contributed two therapies that enable aging or damaged joints to repair themselves rapidly in animal studies.
One is a patented particle-delivery system injected into joints to deliver intermittent bursts of a repurposed regenerative drug over several months.
The other is an engineered protein cocktail injected arthroscopically and allowed to harden in place for precise repair of cartilage lesions.
Columbia University has engineered a living, 3D-printed human knee on a biodegradable scaffold infused with adult stem cells, either from the patient’s body or from a donor.
As the scaffold degrades, the stem cells regenerate natural cartilage and bone, creating a fully load-bearing, non-immunogenic implant that integrates with the body without any need for hardware.
Because it is designed to mirror current artificial joint structures, this innovation allows surgeons to use familiar techniques, which they hope will encourage more physicians to adopt this technique.
The NITRO program is further designed to ensure accessibility, with treatments priced affordably for all Americans regardless of their insurance status.
Additionally, clinical trials will include diverse populations most affected by OA, including women and Native American communities.
Ryan Peterson, MD, a physician with NuView Treatment Center, told Healthline that treating osteoarthritis is currently more about “managing decline” rather than truly healing the condition. Peterson wasn’t involved in the new treatment initiative.
Some may also try treatments such as platelet-rich plasma (PRP), he said, but the results are inconsistent.
Osteoarthritis can be difficult to treat, he added, because it’s a complex condition involving cartilage, bone, inflammation, and the mechanics of the joint.
“Cartilage also has very limited ability to heal, so once damage progresses, we don’t have great ways to reverse it,” said Peterson. “On top of that, pain doesn’t always match imaging, which makes treatment response unpredictable.”
Sergio Guiteau, MD, FAAFP, CAQSM, Medical Director of South Florida Advanced Rejuvenation, agreed with Peterson, adding that there are also degenerative changes affecting the bone underneath the cartilage, the fluid that lubricates the joints, and the ligaments that support the joint. Guiteau wasn’t involved in the new initiative.
“Many of the therapies … address the symptoms of this degeneration, but not the actual disease,” he said.
Guiteau had positive thoughts to share about these new developments.
“If even marginally successful, some of the new therapies through ARPA-H could be game-changing for many of us who take care of patients with OA and life changing for patients,” he said.
Guiteau went on to say that shifting OA treatment from symptom management to structural restoration would be the “holy grail” of OA management.
“If successful, interventions like regenerative injections, protein signaling therapies, or scaffold-based joint reconstruction could for the first time stimulate the body to rebuild cartilage and restore joint integrity,” he said.
According to Guiteau, this would allow millions of OA patients to regain at least some of their independence and achieve a better quality of life.
He did, however, stress that we should remain cautiously optimistic regarding these experimental new treatments.
“Animal studies do not always translate into successful human outcomes, and many companies and individuals are too often quick to capitalize off of the desperation and naivety of those suffering from OA,” he said.
Still, if proven safe and effective, the innovations could mark a long-awaited shift toward restoring joint health rather than simply managing symptoms, providing improved function and pain relief for millions of people who live with this condition.
